Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

RegulatoryZasocitinibPositive

AI Analysis

Summary

Takeda Pharmaceutical's Zasocitinib has received Priority Review status from the FDA for the treatment of psoriasis. The priority designation accelerates the regulatory timeline for this therapeutic candidate.

Outcome Details

Priority Review granted

Importance:6/10

Sentiment:

0.60

FDAPriority ReviewDermatologyNDA

Related Companies

$TAK

Read the original article

Published by yahoo_finance on September 17, 2026 5:08 PM

Read Original